Reduced rate of cardiovascular death after cytomegalovirus prophylaxis in renal transplant recipients

Transplantation

Volumn 99, Issue 6, 2015, Pages 1197-1202

  Opelz, Gerhard ^a   Döhler, Bernd ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; ADOLESCENT; CARDIOVASCULAR DISEASES; CYTOMEGALOVIRUS INFECTIONS; DONOR; EPIDEMIOLOGY; GERMANY; GRAFT SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REGISTER; TRANSMISSION; YOUNG ADULT;

ANTIVIRUS AGENT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CARDIOVASCULAR DISEASES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GERMANY; GRAFT SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; TISSUE DONORS; TRANSPLANT RECIPIENTS; YOUNG ADULT;

EID: 84930537940     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000522     Document Type: Article

References (31)

1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601.
2. SmedbrÅten YV, Sagedal S, Leivestad T, et al. The impact of early cytomegalovirus infection after kidney transplantation on long-term graft and patient survival. Clin Transplant 2014;28:120.
3. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004;66:329.
4. Kotton CN, KumarD, Caliendo AM, et al.; Transplantation Society International CMV Consensus Group. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013;96:333.
5. De Keyzer K, Van Laecke S, Peeters P, et al. Human cytomegalovirus and kidney transplantation: A clinician's update. Am J Kidney Dis 2011;58:118.
6. Hodson EM, Ladhani M, Webster AC, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013;2:CD003774.
7. Opelz G, Döhler B, Ruhenstroth R. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A Collaborative Transplant Study report. Am J Transplant 2004;4:928.
8. Kuo HT, Ye X, Sampaio MS, et al. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis. Transplantation 2010;90:1091.
9. Borchers AT, Perez R, Kaysen G, et al. Role of cytomegalovirus infection in allograft rejection: A review of possible mechanisms. Transpl Immunol 1999;7:75.
10. Vossen RC, Dam-Mieras MC, Bruggeman CA. Cytomegalovirus infection and vessel wall pathology. Intervirology 1996;39:213.
11. Yilmaz S, Koskinen PK, Kallio K, et al. Cytomegalovirus infectionenhanced chronic kidney allograft rejection is linked with intercellular adhesion molecule-1 expression. Kidney Int 1996;50:526.
12. Toupance O, Bouedjoro-Camus MC, Carquin J, et al. Cytomegalovirusrelated disease and risk of acute rejection in renal transplant recipients: A cohort study with case-control analyses. Transpl Int 2000;13:413.
13. Sagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002;2:850.
14. Reischig T, Jindra P, Hes O, et al. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 2009;87:436.
15. Kalil AC, Levitsky J, Lyden E, et al. Meta-Analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005;143:870.
16. SchnitzlerMA. Costs and consequences of cytomegalovirus disease. Am J Health Syst Pharm2003;60(23 Suppl 8):S5.
17. Couchoud C, Cucherat M, Haugh M, et al. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: A meta-Analysis. Transplantation 1998;65:641.
18. Humar A, Gillingham K, Payne WD, et al. Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease. Transplantation 2000;70:310.
19. Courivaud C, Bamoulid J, Chalopin JM, et al. Cytomegalovirus exposure and cardiovascular disease in kidney transplant patients. J Infect Dis 2013;207:1569.
20. Popovi M, Smiljani K, Dobutovi B, et al. Human cytomegalovirus infection and atherothrombosis. J Thromb Thrombolysis 2012;33:160.
21. Caposio P, Orloff SL, Streblow DN. The role of cytomegalovirus in angiogenesis Virus Res 2011;157:204.
22. Grahame-Clarke C. Human cytomegalovirus, endothelial function and atherosclerosis. Herpes 2005;12:42.
23. Stassen FR, Vega-Córdova X, Vliegen I, et al. Immune activation following cytomegalovirus infection: more important than direct viral effects in cardiovascular disease? J Clin Virol 2006;35:349.
24. Foley RN, Parfrey PS, SarnakMJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9(12 Suppl.): S16.
25. Aakhus S, Dahl K, Widerøe TE. Cardiovascular disease in stable renal transplant patients in Norway: morbidity and mortality during a 5-yr follow-up. Clin Transplant 2004;18:596.
26. GrattanMT, Moreno-CabralCE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;261:3561.
27. Avery RK. Viral triggers of cardiac-Allograft dysfunction. N Engl J Med 2001;344:1545.
28. Valantine HA, Gao SZ, Menon SG, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: A post hoc analysis of data from a randomized, placebo-controlled trial. Circulation 1999;100:61.
29. Opelz G, Döhler B. Association of HLA mismatch with death with a functioning graft after kidney transplantation: A collaborative transplant study report. Am J Transplant 2012;12:3031.
30. Opelz G, Döhler B. Association between steroid dosage and death with a functioning graft after kidney transplantation. Am J Transplant 2013;13:2096.
31. Lentine KL, Costa SP, Weir MP, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: A scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant Surgeons, American Society of Transplantation, and National Kidney Foundation. Circulation 2012;126:617.